Skip Navigation LinksHome > March 2006 - Volume 25 - Issue 3 > How Soon After a Prior Tetanus-Diphtheria Vaccination Can On...
Pediatric Infectious Disease Journal:
doi: 10.1097/01.inf.0000202082.56403.c4
Original Studies

How Soon After a Prior Tetanus-Diphtheria Vaccination Can One Give Adult Formulation Tetanus-Diphtheria-Acellular Pertussis Vaccine?

Halperin, Scott A. MD*†; Sweet, Lamont MD§; Baxendale, Darlene BScN*; Neatby, Anne MN§; Rykers, Petra BSc*; Smith, Bruce PhD‡; Zelman, Mitchell MD§; Maus, Diane BSN¶; Lavigne, Pierre MD∥; Decker, Michael D. MD, MPH¶

Collapse Box


Background: Adult formulation tetanus and diphtheria toxoids and acellular pertussis vaccines (Tdap) have been developed to prevent pertussis in adolescents and adults. There are concerns that unacceptable rates of severe injection site reactions, including Arthus-type reactions might occur if Tdap is administered too soon after a previous tetanus and diphtheria toxoid-containing vaccine formulated for infants and younger children (TD) or older children and adults (Td).

Methods: To evaluate whether adverse reactions after Tdap might be related to time since last receipt of TD/Td, we performed an open label, province-wide, clinical trial comparing the reactogenicity of Tdap given 18 months–9 years versus ≥10 years after a previous TD/Td.

Results: Seven thousand one hundred fifty-six children and adolescents were enrolled in the study (464–963 subjects per cohort), and 7001 had documented dates of the previous immunization within the specified intervals; adverse event data were provided by 5931 (84.7%). No whole limb swelling, Arthus-like reactions or serious adverse events related to vaccination were reported. No differences in reports of fever were found by interval since last immunization. Injection site erythema and swelling were slightly and statistically significantly increased among those participants with most recent prior TD/Td. Compared with the 10-year interval group, the maximum increase for any other group was ≤8.6% for any erythema, ≤6% for erythema >10 mm, ≤10.3% for any swelling, ≤6.9% for swelling >10 mm, ≤5.2% for any pain and ≤3.7% for moderate/severe pain.

Conclusion: Although there is a slight increase in injection site events with decreasing interval since a previous immunization, Tdap can be safely administered at intervals of ≥18 months since a previous TD/Td vaccine.

© 2006 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.